CATHEPSIN-D IN PRIMARY BREAST-CARCINOMA - ADVERSE PROGNOSIS IS ASSOCIATED WITH EXPRESSION OF CATHEPSIN-D IN STROMAL CELLS
CATHEPSIN-D IN PRIMARY BREAST-CARCINOMA - ADVERSE PROGNOSIS IS ASSOCIATED WITH EXPRESSION OF CATHEPSIN-D IN STROMAL CELLS
复制标题
DOI：
10.1007/bf00682721
复制
发表时间：
1995-02-01
影响因子：
3.8
通讯作者：
ELLIS, IO
中科院分区：
文献类型：
--
作者：
ODONOGHUE, AEMA;POLLER, DN;ELLIS, IO
用多克隆抗体NCL-CDp检测了连续103例原发性可手术乳腺癌中天冬氨酸蛋白酶组织蛋白酶D的免疫组织化学表达。在所有肿瘤的上皮和基质成分中都发现了组织蛋白酶D的表达。上皮肿瘤成分中组织蛋白酶D表达的增加与常规预后指标（如肿瘤大小、分级、淋巴结分期或患者生存）没有显著关联。然而，间质组织蛋白酶D表达增加与高肿瘤分级显著相关，chi(2) = 11.40 (df = 2), p = 0.003；局部复发倾向增加，chi(2) = 6.87 (df = 1), p = 0.009；区域复发，chi(2) = 7.44 (df = 1), p = 0.006；无病生存率较低，chi(2) = 14.9 (df = 1), p = 0.0001；患者总生存率较低，chi(2) = 6.90 (df = 1), p = 0.0086。组织蛋白酶D在所有乳腺肿瘤中均有表达。基质组织蛋白酶D的表达是一个被忽视的免疫组化预后参数，这可以解释之前一些关于乳腺癌组织蛋白酶D的生化（即总）和免疫组化估计对患者预后影响的明显矛盾的报道。
The immunohistochemical expression of the aspartyl protease enzyme cathepsin D was examined in a consecutive series of 103 primary operable breast carcinomas with the polyclonal antibody NCL-CDp. Expression of cathepsin D was identified within the epithelial and stromal components of all tumours examined. No significant associations of increased cathepsin D expression in the epithelial tumour component with conventional prognostic indices such as tumour size, grade, lymph node stage, or patient survival were identified. However, significant associations of increased stromal cathepsin D expression and high tumour grade, chi(2) = 11.40 (df = 2), p = 0.003; increased tendency to local recurrence, chi(2) = 6.87 (df = 1), p = 0.009; regional recurrence, chi(2) = 7.44 (df = 1), p = 0.006; poorer disease free survival, chi(2) = 14.9 (df = 1), p = 0.0001; and poorer overall patient survival, chi(2) = 6.90 (df = 1), p = 0.0086, were identified. Cathepsin D expression is present in all breast tumours. Stromal cathepsin D expression is a neglected immunohistochemical prognostic parameter which could explain some of the previous apparently conflicting reports concerning the effect on patient prognosis of biochemical (i.e. total) and immunohistochemical estimations of cathepsin D in breast cancers.